Clinical Trial Update: OnabotulinumtoxinA Bladder Injection Study [Phase 4]

View source ↗

Summary

Phase 4 trial of onabotulinumtoxinA injected into the bladder for overactive bladder has been terminated; results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Overactive Bladder
• Overactive Bladder Syndrome
• Urinary Incontinence
• Urinary Urgency

Drugs mentioned

• OnabotulinumtoxinA (botulinum toxin type A)

Snippet

Sponsor: Corewell Health East | Conditions: Overactive Bladder, Overactive Bladder Syndrome | Phase 4 | Status: TERMINATED | Results posted: 2022-02-10